Trial reportBMC medicine2025
Fecal microbiota transplantation for refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a pilot open-label, non-placebo-controlled study.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06938165 (The Safety and Efficacy of Fecal Microbiota Transplant for Steroid-refractory Graft-versus-host Disease), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Fecal Microbiota Transplant for Steroid-refractory Graft-versus-host Disease
Who cites it
8 citing papers in PubMed.
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.Annals of hematology · 2026Article
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- The Role of Gut Microbiota in Acute Myeloid Leukemia.Journal of clinical medicine · 2026Review
- PD-1 deficiency reshapes the TCRβ repertoire and T-cell developmental programs associated with susceptibility to lupus-like autoimmunity.Frontiers in immunology · 2026Article
- Fecal microbiota transplantation: from empirical remedy to precision medicine.Frontiers in microbiomes · 2026Review
- Advances in Understanding the Impact of Human Gut Microbiota on Chemotherapy-Induced Neutropenia.Biomedicines · 2025Review
- Review
- Fecal microbiota transplantation as salvage therapy for disseminated strongyloidiasis in an immunosuppressed patient: a case report.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundDysbiosis of the intestinal microbiota plays a crucial role in the initiation and development of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) has been reported to be effective for refractory acute GVHD; however, whether FMT is effective for refractory chronic GVHD (cGVHD) remains unknown.
methodsTo investigate the efficacy and safety of FMT for refractory cGVHD and the underlying mechanism, 12 patients with refractory cGVHD received FMT via colonoscopy, and the response was evaluated at 12 weeks after FMT.
resultsAmong the 12 patients who underwent FMT, 1 patient achieved a complete response, and 5 patients achieved a partial response. Patients with refractory cGVHD presented lower α diversity and higher abundance of Escherichia-Shigella and Enterobacteriaceae. FMT increased gut microbial diversity, increased the abundance of short-chain fatty acid (SCFA)-producing bacteria, and decreased the abundance of Escherichia-Shigella and Enterobacteriaceae in responder patients. Moreover, it increased SCFA levels in fecal samples from the responder group and promoted the expansion of peripheral CD4
conclusionsThe results of the present study suggest that FMT is feasible and deserves further investigation for use in patients with refractory cGVHD.
trial registrationClinicalTrials.gov (NCT06938165).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.